European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Marksans Pharma gets USFDA nod for acid reflux drug
Reinforcing commitment to ethical and sustainable growth
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Subscribe To Our Newsletter & Stay Updated